Fig 1.
Activity of F18 against HIV-1NL4-3 wild-type strains and five major subtypes in PBMCs. (A) Structure of 10-chloromethyl-11-demethyl-12-oxo-calanolide A (F18). (B and C) Serially diluted F18, NVP, and (+)-calanolide A were added to PBMCs infected with wild-type HIV-1NL4-3 (B) or five major subtypes (C). The p24 level was measured 7 days PI. Each drug was tested in three PHA-stimulated fresh healthy donor PBMCs. All results are means ± standard errors of the means from three independent experiments.